Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.05 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 09/30/15 All times are local (Market data is delayed by at least 15 minutes).

immudyne inc (IMMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/4/15 - $0.23
52 Week Low
06/16/15 - $0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUDYNE INC (IMMD)

Related News

No related news articles were found.

immudyne inc (IMMD) Related Businessweek News

No Related Businessweek News Found

immudyne inc (IMMD) Details

Immudyne, Inc. develops, manufactures, and sells natural immune support products primarily in the United States. The company offers nutraceutical and cosmetic product lines, including yeast beta glucans that are natural extracts for various oral and topical applications. Its s nutraceutical and cosmetic products for yeast beta glucans are the daily oral supplements, such as dietary supplements to support immune system function; and topical rejuvinating serums and creams that are intended to support the skin’s immune system response and defense, skin renewal, and repair of sun and environmental damage. The company sells its products directly to consumers, as well as to pharmaceutical, nutraceutical, and consumer product companies. Immudyne, Inc. was incorporated in 1987 and is based in Mount Kisco, New York.

3 Employees
Last Reported Date: 03/30/15
Founded in 1987

immudyne inc (IMMD) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $145.6K
Compensation as of Fiscal Year 2014.

immudyne inc (IMMD) Key Developments

ImmuDyne, Inc. Announces Joining of Sven Rohmann to its Board of Directors

ImmuDyne, Inc. announced that Sven Rohmann M.D., PhD, M.B.A. has joined its board of directors. Previously, Dr. Rohmann spent 10 years at Merck Serono and has an excellent track record across scientific, clinical, and commercial markets. During his tenure at Merck, he was instrumental in the successful licensing of Erbitux from ImClone, which has grown to over $1 billion in annual revenues. Sven also played an integral role in the establishment of Merck Oncology.

ImmuDyne, Inc. Announces Revenue Results for the First Quarter of Fiscal 2015

ImmuDyne, Inc. announced revenue results for the first quarter of fiscal 2015. The company announced first quarter revenues rose more than 50%, year over year, to approximately $288,000.

IPA Endorses ImmuDyne Line of Immune Support Supplements

ImmuDyne, Inc. announced that the Independent Pharmacy Alliance will endorse ImmuDyne's full line of Immune Support Products. During the educational process to over 600 IPA members provided by many PhD nutritional experts, discovered ImmuDyne and how its preventative impact affected. This product can be highly recommend for all members, their families and their patients. Because of my experience, IPA has contracted with ImmuDyne at very special and affordable pricing.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMMD:US $0.05 USD 0.00

IMMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMMD.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUDYNE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at